Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

[1] Siegel RL(2016)Cancer statistics, 2017 CA Cancer J Clin 67 7-30

[2] Miller KD(2001)Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 3622-3634

[3] Jemal A(2016)The systemic management of advanced melanoma in 2016 Oncol Res Treat 39 635-642

[4] Balch CM(2016)Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib J Clin Oncol 34 871-878

[5] Soong SJ(2016)Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic J Clin Oncol 34 9502-9502

[6] Gershenwald JE(2014) V600E/K-mutant cutaneous melanoma N Engl J Med 371 1867-1876

[7] Thompson JF(2010)Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 363 711-723

[8] Reintgen DS(2015)Improved survival with ipilimumab in patients with metastatic melanoma Journal Clin Oncol 9 JCO-2014-483

[9] Cascinelli N(2016)Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J Clin Pathol 69 472-94

[10] Heppt MV(1998)Angiogenesis in melanoma: an update with a focus on current targeted therapies Cancer Detect Prev 22 185-2527

[1] Siegel RL(2016)Cancer statistics, 2017 CA Cancer J Clin 67 7-30

[2] Miller KD(2001)Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 3622-3634

[3] Jemal A(2016)The systemic management of advanced melanoma in 2016 Oncol Res Treat 39 635-642

[4] Balch CM(2016)Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib J Clin Oncol 34 871-878

[5] Soong SJ(2016)Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic J Clin Oncol 34 9502-9502

[6] Gershenwald JE(2014) V600E/K-mutant cutaneous melanoma N Engl J Med 371 1867-1876

[7] Thompson JF(2010)Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 363 711-723

[8] Reintgen DS(2015)Improved survival with ipilimumab in patients with metastatic melanoma Journal Clin Oncol 9 JCO-2014-483

[9] Cascinelli N(2016)Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J Clin Pathol 69 472-94

[10] Heppt MV(1998)Angiogenesis in melanoma: an update with a focus on current targeted therapies Cancer Detect Prev 22 185-2527